Ott et al. analyzed PD-L1 expression, the T-cell inflamed gene expression profile (GEP), and non-synonymous tumor mutations assessed by whole exome sequencing (TMB) in patients enrolled in the KEYNOTE-28 trial. The gene discussed is CD274; the disease is neoplasm.